Blosozumab

Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2].

Product Specifications

CAS Number

[1132758-87-2]

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/blosozumab.html

Purity

99.45

Solubility

10 mM in DMSO

Smiles

[Blosozumab]

Molecular Weight

(144.88 kDa)

References & Citations

[1]Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30 (2) :216-24. |[2]Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125 (2) :586-94.